Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Monopar Therapeutics to post earnings of ($0.5123) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 2, 2026 at 9:30 AM ET.
Monopar Therapeutics Trading Down 5.9%
MNPR stock opened at $55.21 on Monday. The stock’s 50 day simple moving average is $60.89 and its 200 day simple moving average is $70.49. Monopar Therapeutics has a 12-month low of $26.06 and a 12-month high of $105.00. The stock has a market capitalization of $368.80 million, a PE ratio of -16.05 and a beta of 1.58.
Analysts Set New Price Targets
Several research firms have recently weighed in on MNPR. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Chardan Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $107.00.
Insider Buying and Selling at Monopar Therapeutics
In other news, CFO Quan Anh Vu purchased 1,500 shares of the stock in a transaction dated Friday, December 26th. The shares were purchased at an average cost of $69.95 per share, with a total value of $104,925.00. Following the acquisition, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at $104,925. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 20.50% of the stock is owned by insiders.
Institutional Trading of Monopar Therapeutics
A number of hedge funds have recently bought and sold shares of MNPR. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics in the third quarter valued at about $28,000. BNP Paribas Financial Markets grew its stake in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $65,000. JPMorgan Chase & Co. increased its position in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics in the 2nd quarter worth approximately $80,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.
About Monopar Therapeutics
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Further Reading
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
